Severe community-acquired pneumonia.
Michael S NiedermanAntoní TorresPublished in: European respiratory review : an official journal of the European Respiratory Society (2022)
Severe community-acquired pneumonia is the most life-threatening form of community-acquired pneumonia, characterised by intensive care unit admission and high morbidity and mortality. In this review article, we cover in depth six aspects of severe community-acquired pneumonia that are still controversial: use of PCR molecular techniques for microbial diagnosis; the role of biomarkers for initial management; duration of treatment, macrolides or quinolones in the initial empirical antibiotic therapy; the use of prediction scores for drug-resistant pathogens to modify initial empiric therapy; the use of noninvasive mechanical ventilation and high-flow nasal oxygen; and the use of corticosteroids as adjunctive therapy in severe community-acquired pneumonia.
Keyphrases
- community acquired pneumonia
- drug resistant
- mechanical ventilation
- intensive care unit
- early onset
- multidrug resistant
- acute respiratory distress syndrome
- emergency department
- acinetobacter baumannii
- drug induced
- stem cells
- single molecule
- cystic fibrosis
- mesenchymal stem cells
- cell therapy
- bone marrow
- combination therapy